UI Hospitals and Clinics
Assessing Nasopharyngeal and Pulmonary Adverse Events that may be Associated Certain Medications
Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution
Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.
Please refer to www.clinicaltrials.gov for more information identifier NCT01266265
Pulmonary Hypertension Program
Cynthia Larew RN 319-356-1028 pager # 2123
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.